Biomedicines (Aug 2024)

Serum Uric Acid as an Indicator of Right Ventricular Dysfunction in LVAD Patients: A Preliminary Study

  • Tomasz Urbanowicz,
  • Małgorzata Tomaszewska,
  • Anna Olasińska-Wiśniewska,
  • Jędrzej Sikora,
  • Ewa Straburzyńska-Migaj,
  • Jakub Piecek,
  • Maksymilian Białasik-Misiorny,
  • Aleksandra Krasińska-Płachta,
  • Andrzej Tykarski,
  • Marek Jemielity

DOI
https://doi.org/10.3390/biomedicines12091935
Journal volume & issue
Vol. 12, no. 9
p. 1935

Abstract

Read online

(1) Background: Left ventricular assist devices (LVADs) represent mechanical support in end-stage congestive heart failure and are characterized by satisfactory long-term results. Uric acid (UA) represents one of the early heart failure markers whose usefulness was postulated in clinical practice. (2) Methods: Twenty-nine male patients with a median age of 58 (51–62) years were referred for LVAD implantation due to end-stage congestive heart failure in the mean (SD) New York Heart Association (NYHA) status class 3.3 (0.6). Preoperative and postoperative right ventricular (RV) characteristics were compared with serum uric acid concentration within 12 (8–15) months following the implantation. (3) Results: Significant correlations between postoperative uric acid concentration and right ventricular dimension (r = 0.604, p = 0.005), tricuspid annulus plane systolic excursion (TAPSE) (r = −0.496, p = 0.022), left ventricular ejection fraction (r = −0.463, p = 0.046), and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) (r = 0.505, p = 0.041) were noted. (4) Conclusions: The analysis shows the association between the postoperative RV diameter and TAPSE results in LVAD patients and uric acid concentration. Serum uric acid can be regarded as a possible right ventricular dysfunction marker in LVAD patients.

Keywords